London
· Delayed Price · Currency is GBP · Price in USD Ultragenyx Pharmaceutical Statistics
Total Valuation
LON:0LIF has a market cap or net worth of GBP 2.75 billion. The enterprise value is 2.88 billion.
| Market Cap | 2.75B |
| Enterprise Value | 2.88B |
Important Dates
The next estimated earnings date is Friday, May 2, 2025.
| Earnings Date | May 2, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +23.11% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 90.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.15 |
| PB Ratio | 13.14 |
| P/TBV Ratio | 105.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.34 |
| EV / Sales | 6.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.56 |
Financial Position
The company has a current ratio of 2.37, with a Debt / Equity ratio of 3.47.
| Current Ratio | 2.37 |
| Quick Ratio | 2.13 |
| Debt / Equity | 3.47 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.16 |
| Interest Coverage | -8.50 |
Financial Efficiency
Return on equity (ROE) is -211.71% and return on invested capital (ROIC) is -28.12%.
| Return on Equity (ROE) | -211.71% |
| Return on Assets (ROA) | -22.37% |
| Return on Invested Capital (ROIC) | -28.12% |
| Return on Capital Employed (ROCE) | -46.23% |
| Revenue Per Employee | 345,823 |
| Profits Per Employee | -351,350 |
| Employee Count | 1,294 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 19.62 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.99% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -15.99% |
| 50-Day Moving Average | 39.29 |
| 200-Day Moving Average | 46.39 |
| Relative Strength Index (RSI) | 57.21 |
| Average Volume (20 Days) | 122 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.55 |
Income Statement
In the last 12 months, LON:0LIF had revenue of GBP 447.49 million and -454.65 million in losses. Loss per share was -5.02.
| Revenue | 447.49M |
| Gross Profit | -171.23M |
| Operating Income | -428.12M |
| Pretax Income | -453.37M |
| Net Income | -454.65M |
| EBITDA | -399.73M |
| EBIT | -428.12M |
| Loss Per Share | -5.02 |
Balance Sheet
The company has 487.27 million in cash and 726.89 million in debt, giving a net cash position of -131.78 million.
| Cash & Cash Equivalents | 487.27M |
| Total Debt | 726.89M |
| Net Cash | -131.78M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 209.51M |
| Book Value Per Share | 2.20 |
| Working Capital | 377.79M |
Cash Flow
In the last 12 months, operating cash flow was -330.84 million and capital expenditures -5.98 million, giving a free cash flow of -336.82 million.
| Operating Cash Flow | -330.84M |
| Capital Expenditures | -5.98M |
| Free Cash Flow | -336.82M |
| FCF Per Share | n/a |
Margins
Gross margin is -38.26%, with operating and profit margins of -95.67% and -101.60%.
| Gross Margin | -38.26% |
| Operating Margin | -95.67% |
| Pretax Margin | -101.31% |
| Profit Margin | -101.60% |
| EBITDA Margin | -89.33% |
| EBIT Margin | -95.67% |
| FCF Margin | n/a |
Dividends & Yields
LON:0LIF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.11% |
| Shareholder Yield | -23.11% |
| Earnings Yield | -16.51% |
| FCF Yield | -12.23% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0LIF has an Altman Z-Score of -2.09. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.09 |
| Piotroski F-Score | n/a |